Onconetix Revises Realbotix Share Exchange Terms and Extends Deadline to March 2027

what happened

Onconetix and Realbotix have revised their share exchange agreement, changing how ownership and cash are handled in the proposed transaction and pushing back the deadline for completing it, according to TradingView, which cites filings with the SEC. Under the amended terms, if the deal closes with net cash under $12.5 million, the seller would hold 95% of Onconetix's fully diluted shares.

Net cash will also count the outstanding principal and accrued interest on a promissory note that Onconetix owes Realbotix. The amendment, signed and effective November 4, 2026, moves the agreement's end date to March 31, 2027.

why it matters

For Onconetix shareholders, the revised terms change how control of the company would be split, and the promissory note now feeds directly into the cash calculation that drives that split. Moving the deadline to March 2027 suggests the parties are not yet close to finishing the transaction. Cash position and debt owed to Realbotix are worth tracking in future filings.

tags

instruments